Zohar Sachs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2101077/publications.pdf

Version: 2024-02-01

933447 839539 30 351 10 18 citations h-index g-index papers 30 30 30 732 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress. Molecular Cell, 2016, 61, 625-639.	9.7	59
2	Human Melanoma-Derived Extracellular Vesicles Regulate Dendritic Cell Maturation. Frontiers in Immunology, 2017, 8, 358.	4.8	54
3	Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia. Cancer Research, 2020, 80, 458-470.	0.9	46
4	Double- and triple-hit lymphomas can present with features suggestive of immaturity, including TdT expression, and create diagnostic challenges. Leukemia and Lymphoma, 2016, 57, 2626-2635.	1.3	34
5	NRAS G12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia. Blood, 2014, 124, 3274-3283.	1.4	24
6	Synthesis and antileukemic activities of C1–C10-modified parthenolide analogues. Bioorganic and Medicinal Chemistry, 2015, 23, 4737-4745.	3.0	23
7	Utilization of Translational Bioinformatics to Identify Novel Biomarkers of Bortezomib Resistance in Multiple Myeloma. Journal of Cancer, 2014, 5, 720-727.	2.5	20
8	Monosomal Karyotype at the Time of Diagnosis or Transplantation Predicts Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2015, 21, 866-872.	2.0	19
9	Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency. Haematologica, 2016, 101, 1190-1199.	3.5	14
10	Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival. Journal of Proteome Research, 2019, 18, 1842-1856.	3.7	14
11	Novel single-cell technologies in acute myeloid leukemia research. Translational Research, 2017, 189, 123-135.	5.0	9
12	Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer Journal, 2021, 11, 18.	6.2	8
13	Primary Cardiac Lymphoma: Three Case Reports and a Review of the Literature. Open Journal of Blood Diseases, 2021, 11, 120-132.	0.1	6
14	High risk of relapse with intermediate dose cytarabine for consolidation in young favourableâ€risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature. British Journal of Haematology, 2021, 194, 140-144.	2.5	5
15	Sarcoid-like Histiocytic Proliferations in Patients With Lymphoma Can Be FDG-avid Concerning for Refractory or Recurrent Disease. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e597-e601.	0.4	3
16	Proteasome Inhibition Attenuates Self-Renewal in Human Acute Myeloid Leukemia By Targeting NF-Kappa B in Leukemia Stem Cells. Blood, 2021, 138, 3347-3347.	1.4	3
17	Buccal epithelial cells display somatic, bone marrow–derived CALR mutation. Blood Advances, 2017, 1, 2302-2306.	5.2	2
18	Prognostic factors for clinical outcomes of patients with central nervous system leukemia. Hematology/ Oncology and Stem Cell Therapy, 2020, 14, 240-245.	0.9	2

#	Article	IF	CITATIONS
19	High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3. Blood, 2019, 134, 3432-3432.	1.4	2
20	JAK/STAT Inhibition Targets TP53 altered Primary Human Acute Myeloid Leukemia Stem Cells. Blood, 2020, 136, 27-28.	1.4	2
21	Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome. Leukemia Research, 2020, 95, 106404.	0.8	1
22	Germline Calr Mutation and Thrombocytosis Presenting with Concomitant BCR-ABL1+ CML. Blood, 2016, 128, 5494-5494.	1.4	1
23	86: CALR Mutation Thrombocytosis Following Imatinib Treatment for BCR-ABL1+ Chronic Myelogenous Leukemia: A Case of Concomitant Genetic Alterations in an Overlap Myeloproliferative Neoplasm. American Journal of Clinical Pathology, 2015, 143, A049-A049.	0.7	0
24	Oncogene Withdrawal Selectively Alters Phosphoprotein States and Shifts Differentiation Status In Myeloid Leukemia Subpopulations. Blood, 2010, 116, 3160-3160.	1.4	0
25	Delineating Critical Effectors of Remission Induction in a Mouse Model of AML. Blood, 2011, 118, 5232-5232.	1.4	0
26	Activated NRAS Mediates Self-Renewal Capacity in AML by Facilitating the Mll/AF9-Specified Gene Expression Signature. Blood, 2012, 120, 5116-5116.	1.4	0
27	Are IPSS-R and IPSS Cytogenetic Risk Stratification Informative At the Time of Allogeneic Hematopoietic Cell Transplantation?. Blood, 2012, 120, 1400-1400.	1.4	0
28	Ras-Pathway Inhibition With Targeted Therapies Abrogates Self-Renewal In Acute Myelogenous Leukemia. Blood, 2013, 122, 819-819.	1.4	0
29	Immunoproteasome Inhibition to Target AML with Activated RAS Pathways. Blood, 2016, 128, 577-577.	1.4	0
30	Clinical Value of Next Generation Sequencing in the Detection of Recurring Structural Rearrangements and Copy Number Abnormalities in Acute Myeloid Leukemia. Blood, 2020, 136, 21-22.	1.4	0